HER2 Support Group Forums - View Single Post - use of the ATP-CRA test to determine the most effective chemotherapy regimen.

Rich66 · 04-05-2009, 11:56 PM

1: J Int Med Res. 2007 Nov-Dec;35(6):753-61. Links: Correlation between the in vitro ATP-based chemosensitivity assay and HER2/neu expression in women with breast cancer.

Woo SU, Bae JW, Kim HG, Choi SH, Kang DH, Lee JB, Koo BW.
Department of Surgery, Korea University College of Medicine, Seoul, Korea.
Several in vitro chemosensitivity tests have been developed to predict the chemotherapeutic response of tumours prior to initiation of individualized treatment for breast cancer. This study investigated whether the in vitro chemosensitivity response of cell lines derived from breast cancer patients was affected by HER2/neu expression. We cultured breast cancer cell lines from 50 patients and the adenosine triphosphatebased chemotherapy response assay (ATPCRA) was performed with 5-fluorouracil, gemcitabine, docetaxel, doxorubicin, methotrexate, vinorelbine and paclitaxel. 5-fluorouracil combined a high median cell death rate (32.4%) with the narrowest range of cytotoxic effects (7.3-65.7%). In addition, gemcitabine showed significantly greater activity in HER2/neupositive patients. In contrast, docetaxel was significantly less effective in HER2/neu-positive patients. No significant correlation was found between the other agents and HER2/neu expression. The use of the ATP-CRA test for metastatic tissue from patients with recurrent disease might be a useful approach to determine the most effective chemotherapy regimen.

04-05-2009, 11:56 PM	#1
Rich66 Senior Member Join Date: Feb 2008 Location: South East Wisconsin Posts: 3,431	use of the ATP-CRA test to determine the most effective chemotherapy regimen. 1: J Int Med Res. 2007 Nov-Dec;35(6):753-61. Links Correlation between the in vitro ATP-based chemosensitivity assay and HER2/neu expression in women with breast cancer. Woo SU, Bae JW, Kim HG, Choi SH, Kang DH, Lee JB, Koo BW. Department of Surgery, Korea University College of Medicine, Seoul, Korea. Several in vitro chemosensitivity tests have been developed to predict the chemotherapeutic response of tumours prior to initiation of individualized treatment for breast cancer. This study investigated whether the in vitro chemosensitivity response of cell lines derived from breast cancer patients was affected by HER2/neu expression. We cultured breast cancer cell lines from 50 patients and the adenosine triphosphatebased chemotherapy response assay (ATPCRA) was performed with 5-fluorouracil, gemcitabine, docetaxel, doxorubicin, methotrexate, vinorelbine and paclitaxel. 5-fluorouracil combined a high median cell death rate (32.4%) with the narrowest range of cytotoxic effects (7.3-65.7%). In addition, gemcitabine showed significantly greater activity in HER2/neupositive patients. In contrast, docetaxel was significantly less effective in HER2/neu-positive patients. No significant correlation was found between the other agents and HER2/neu expression. The use of the ATP-CRA test for metastatic tissue from patients with recurrent disease might be a useful approach to determine the most effective chemotherapy regimen.